Private anti-VEGF wet AMD injections London

Symptoms of wet AMD — when to ring the same day

Wet AMD is a medical retina emergency. Vision lost in the first 6 weeks of untreated wet AMD is often not recoverable. Ring 0800 852 7782 the same day if any of the following develop in either eye, especially if you are over 50 or have a known dry AMD diagnosis:

• New central distortion — straight lines (door frames, lamp posts, the lines of an Amsler grid) suddenly look wavy, broken or kinked.
• New central blind spot (scotoma) — a smudge, dark patch or missing area in the centre of vision.
• Sudden central blur in one eye that does not clear with blinking or new glasses.
• Drop in reading vision — you can no longer read newsprint or your phone with one eye.
• Faded or washed-out colours centrally in one eye.

The hallmark feature is that the symptom is central, unilateral (or worse in one eye than the other) and has appeared over days, not months. Floaters with flashes of light are usually a different problem: vitreous detachment or retinal tear — ring the same day for triage either way.

Same-day diagnosis at the consultant medical retina clinic

The same-day private medical retina pathway runs in a single 60–90 minute appointment:

1. Visual acuity on an ETDRS chart, Amsler grid in each eye, refraction.
2. Slit-lamp biomicroscopy of the anterior segment and dilated fundus exam.
3. Spectral-domain or swept-source OCT macula (Heidelberg Spectralis, Zeiss Cirrus, Topcon Triton or DRI OCT) — the single most important test in wet AMD; defines intra-retinal, sub-retinal and sub-RPE fluid.
4. OCT angiography (OCTA) — non-invasive, dye-free imaging of the choroidal neovascularisation network.
5. Fundus autofluorescence — defines geographic atrophy and disease extent.
6. Fundus fluorescein angiography (FFA) where the lesion is occult or atypical.
7. Indocyanine green angiography (ICGA) where polypoidal choroidal vasculopathy or RAP is suspected (more common in patients of Asian or African descent).

The consultant medical retina specialist confirms the diagnosis, the lesion subtype and the right anti-VEGF agent at the same visit, and the first loading injection is given the same day where indicated.

What is anti-VEGF intravitreal injection therapy?

Wet (neovascular) AMD is the abrupt new-vessel-and-fluid form of macular degeneration that affects around 10 per cent of all AMD patients but causes the majority of severe AMD vision loss. The disease driver is over-expression of vascular endothelial growth factor (VEGF) by stressed retinal pigment epithelium, which provokes new fragile blood vessels (choroidal neovascularisation, CNV) to grow up from the choroid, leak fluid and blood under and into the retina, and lift the macula away from its underlying nourishment.

Anti-VEGF intravitreal injection therapy blocks VEGF in the vitreous cavity, dries up the new vessels, resorbs intraretinal and subretinal fluid and stabilises (and often improves) central vision. Anti-VEGF therapy revolutionised AMD care from 2006 onwards (MARINA / ANCHOR ranibizumab trials) and is now the consultant-led standard of care worldwide. The same drugs are used in diabetic macular oedema, retinal vein occlusion, polypoidal choroidal vasculopathy, myopic CNV and other neovascular retinal disease. Read more: Wet AMD (condition) · Dry AMD (condition) · Private diabetic eye screening.

Which anti-VEGF drug is right for me in 2026?

UK 2026 has six anti-VEGF agents in routine clinical use. The consultant medical retina specialist recommends the right drug for your lesion subtype, fluid pattern, baseline acuity, prior treatment response, systemic risk profile and your preference for fewer injections.

• Eylea HD 8 mg aflibercept (Bayer) — four-fold higher concentration than original Eylea; PULSAR 96-week trial showed non-inferior visual outcomes with longer dosing intervals (12 to 16 weeks in many patients). Approved by NICE TA800 in 2024. The most common 2026 first-line drug for treatment-naïve wet AMD.
• Vabysmo (faricimab 6 mg, Roche) — the first bispecific antibody for the eye, blocking both VEGF-A and angiopoietin-2. TENAYA and LUCERNE trials showed non-inferiority to Eylea 2 mg with extended dosing in many patients. Approved by NICE TA672. Particularly attractive for patients with persistent fluid on aflibercept.
• Eylea 2 mg aflibercept (Bayer) — the original aflibercept, 8-week dosing after loading; the gold-standard reference drug for almost two decades. NICE TA294.
• Lucentis (ranibizumab 0.5 mg, Novartis) — the original wet AMD anti-VEGF (MARINA / ANCHOR 2006); NICE TA155.
• Ranibizumab biosimilars — Byooviz and Ximluci are MHRA-approved biosimilars to Lucentis at lower cost; clinically equivalent.
• Beovu (brolucizumab 6 mg, Novartis) — single-chain antibody fragment with longer durability; HAWK / HARRIER trials. UK use limited by higher rate of intra-ocular inflammation and occlusive retinal vasculitis.
• Avastin (bevacizumab 1.25 mg, Roche) — off-label, compounded; CATT and IVAN trials showed clinical equivalence to Lucentis; the cheapest option but the licence is for cancer not retina, requiring informed consent and a compounding pharmacy.

How is the injection performed?

The intravitreal injection is performed in a CQC-registered clean-room procedure suite. You walk in, sit in a reclining chair, the injection takes around two seconds and you walk out within the hour. Step-by-step:

1. Anaesthesia — topical proxymetacaine 0.5 per cent drops; a sub-conjunctival lidocaine 2 per cent pledget for 60 seconds at the planned injection site.
2. Antiseptic prep — 5 per cent povidone-iodine to the lids and conjunctival fornix; sterile drape and lid speculum.
3. Injection — the anti-VEGF drug is drawn into a 30 to 32-gauge needle and injected through the pars plana 3.5 to 4.0 mm posterior to the limbus (3.0 mm in pseudophakic eyes) into the vitreous cavity.
4. Confirmation of perfusion — hand-movements vision is checked immediately to confirm the central retinal artery is patent.
5. Post-injection — the eye is irrigated with sterile saline; topical antibiotic prophylaxis is not routinely required (RCO guidance 2024).

You will see floaters (the drug bubble) for an hour or two; vision returns to baseline by the next morning. Mild gritty discomfort from the iodine prep settles in 12 to 24 hours; small subconjunctival haemorrhages are common and self-limiting.

Loading and treat-and-extend (T&E) maintenance

Almost all wet AMD patients follow the same protocol shape:

• Loading dose — three monthly intravitreal injections at weeks 0, 4 and 8.
• Re-evaluation — OCT macula at week 12; the consultant decides whether to continue monthly, switch drug or move to T&E.
• Treat-and-extend (T&E) from week 12 — each visit combines OCT, the next anti-VEGF injection on the same day and a planned next interval. The consultant extends the interval by 2-week steps when the macula is dry and shortens it by 2-week steps when fluid recurs.
• Maintenance interval — most patients reach 8 to 16 weeks; many Eylea HD or Vabysmo patients extend to 12, 16 or 20 weeks within 12 to 24 months.
• Lifelong — wet AMD is a chronic disease; lifelong consultant medical retina monitoring with OCT is essential.

T&E is supported by NICE TA672, NICE TA800, the EURETINA wet AMD position statement and the RCO Medical Retina Commissioning Standards as the optimal balance of visual outcome and treatment burden. Pure pro-re-nata (PRN, treat only when fluid is seen) protocols are no longer recommended — they under-treat too many patients.

UK 2026 private anti-VEGF injection price table

Drug	UK 2026 price (per injection per eye)	Best for
Eylea HD 8 mg aflibercept	£1,400–£1,800	Treatment-naïve wet AMD; longer interval
Vabysmo (faricimab 6 mg)	£1,400–£1,800	Persistent fluid on aflibercept; PCV
Eylea 2 mg aflibercept	£1,100–£1,500	Gold-standard 8-week dosing
Lucentis (ranibizumab 0.5 mg)	£1,000–£1,400	Original gold-standard; long safety record
Ranibizumab biosimilars (Byooviz, Ximluci)	£900–£1,200	Lower-cost equivalent to Lucentis
Beovu (brolucizumab 6 mg)	£1,200–£1,600	Selected cases; longer interval; inflammation risk
Avastin (bevacizumab 1.25 mg, off-label)	£700–£1,000	Cost-constrained; informed off-label consent

Prices are UK 2026 self-pay, all-inclusive (consultant medical retina specialist, drug, sterile clean-room injection pack, OCT, structured 4-week follow-up). Three-month loading dose: 2,700 to 5,400 pounds. Annual maintenance on T&E: 4,000 to 10,000+ pounds depending on drug and interval.

What is included in the all-inclusive private wet AMD fee?

• Consultant medical retina specialist — UK GMC-registered consultant ophthalmologist with medical retina subspecialty fellowship and a published anti-VEGF volume.
• Same-day diagnostic work-up — visual acuity, refraction, slit-lamp examination, dilated fundus exam, spectral-domain or swept-source OCT macula, OCT angiography, fundus autofluorescence and (where indicated) fundus fluorescein angiography and indocyanine green angiography.
• Anti-VEGF drug — the chosen agent (Eylea HD, Vabysmo, Eylea 2 mg, Lucentis, ranibizumab biosimilar, Beovu or off-label Avastin).
• Sterile clean-room injection suite — CQC-registered procedure suite, sterile injection pack, povidone-iodine prep, sub-conjunctival lidocaine pledget, drape and lid speculum.
• OCT macula at every maintenance visit — same-day imaging directly informing the next T&E interval.
• Structured follow-up — week-4 and week-12 OCT during loading; thereafter every visit on T&E.
• Out-of-hours consultant access — 24/7 cover for any new central distortion, eye pain, redness or vision drop in the first 30 days after each injection.

NHS vs private wet AMD treatment in the UK in 2026

Wet AMD is fully commissioned on the NHS in 2026 under NICE TA155 (ranibizumab), TA294 (aflibercept 2 mg), TA672 (faricimab) and TA800 (aflibercept HD 8 mg). The current NHS challenge is capacity, not commissioning: most UK NHS macular clinics run a 1 to 4-week wait between diagnosis and the first injection, with onward waits for maintenance visits in some regions.

Choose the NHS pathway when your high-street optometrist's macular OCT and the urgent NHS macular fast-track referral can deliver a first injection within 1 to 2 weeks of symptom onset. Choose the private pathway when same-day diagnosis-to-injection matters (recurrent or rapidly progressing disease, fellow-eye conversion, second-eye threat, work or travel constraints), when you want a specific newer drug (Eylea HD or Vabysmo) and your local NHS trust is not yet using it routinely, when consultant continuity matters across loading and T&E maintenance, or when geography and clinic timing work better in the private sector. Many patients combine the two: private same-day pathway for diagnosis and loading dose, then transfer to NHS for maintenance.

Insurance cover for wet AMD treatment in 2026

Bupa, AXA Health, Aviva, Vitality and WPA all cover diagnosis and full anti-VEGF treatment of wet AMD in 2026, with pre-authorisation:

• Diagnostic work-up — consultant medical retina assessment, OCT, OCTA and FFA are covered.
• Loading dose — the three monthly injections are covered as a single treatment episode.
• Maintenance T&E — covered subject to annual or per-condition caps. Some policies cap at 6 to 12 injections per year per eye; the consultant team writes the supporting letter where caps need to be raised.
• Drug choice — newer drugs (Eylea HD, Vabysmo) are usually reimbursed at the same rate as Eylea 2 mg or Lucentis once the consultant has documented the clinical rationale.
• Pre-existing exclusions — moratorium policies will check for pre-existing AMD diagnosis. Discuss with your insurer's pre-authorisation team before booking.
• Excess — standard policy excess applies; the clinic billing team confirms the excess at the time of pre-authorisation.

What does the evidence say?

Anti-VEGF for wet AMD is one of the most thoroughly studied treatments in medicine. Headline results from the UK and international evidence base:

• MARINA (ranibizumab, n=716, 2006) — the foundational ranibizumab trial; 95 per cent of patients lost less than 15 letters at 24 months vs 62 per cent on sham; 34 per cent gained 15 letters or more.
• ANCHOR (ranibizumab vs PDT, n=423) — ranibizumab clearly superior to verteporfin photodynamic therapy.
• VIEW 1 and VIEW 2 (aflibercept 2 mg, n=2,419) — aflibercept 2 mg every 8 weeks non-inferior to ranibizumab every 4 weeks at 96 weeks.
• HARBOR (ranibizumab dose / regimen) — pure PRN under-treats; T&E gives the best balance.
• CATT (Lucentis vs Avastin) — clinical equivalence at 1 and 2 years; informs off-label Avastin use.
• IVAN (UK) — same conclusion; informs UK NHS Avastin use under NHS-England policy.
• TENAYA / LUCERNE (Vabysmo, n=1,329, 2-year) — faricimab 6 mg non-inferior to aflibercept 2 mg with extended dosing in many patients.
• PULSAR (Eylea HD 8 mg, 96-week) — aflibercept HD non-inferior to aflibercept 2 mg with dosing intervals of 12 to 16 weeks in many patients; underpins NICE TA800 (2024).
• HAWK / HARRIER (brolucizumab) — non-inferior to aflibercept 2 mg; higher rate of intra-ocular inflammation tempered enthusiasm.
• UK NHS Liverpool real-world dataset — the largest real-world UK dataset; confirms trial-grade outcomes are achievable in everyday NHS practice.

Risks and what can go wrong

• Endophthalmitis — sight-threatening intra-ocular infection; rate 1 in 2,000 to 1 in 5,000 injections; presents as new pain, redness and vision drop within 1 to 7 days. Same-day clinic call if any symptom.
• Sterile intra-ocular inflammation — 1 in 200 to 1 in 1,000 injections (higher with brolucizumab, around 1 in 50 to 1 in 100); usually settles with topical and oral steroid.
• Occlusive retinal vasculitis (brolucizumab) — rare but serious; reason for limited UK 2026 brolucizumab use.
• Transient IOP spike — settles in minutes to hours; rarely needs treatment.
• Sub-conjunctival haemorrhage — common, painless, self-limiting in 1 to 2 weeks.
• Retinal tear or detachment — less than 1 in 10,000 injections.
• Cataract progression — from repeated trauma; manage with private cataract surgery when visually significant.
• Systemic risk (stroke, MI) — extensively studied; small absolute risk; balanced against the visual benefit; particular caution within 3 months of stroke or TIA.
• RPE tear — in eyes with a large pigment epithelial detachment; risk discussed at consent.
• Treatment failure — around 5 to 10 per cent of patients continue to lose vision despite optimal anti-VEGF; switch drug, increase frequency or consider trial.

Monitoring — what you can do at home

• Daily Amsler grid — one eye at a time, at the same distance and lighting; ring same-day for any new wavy line, blurred patch or blind spot.
• ForeseeHome / monitored OCT — home device that detects subtle changes in macular function and alerts the clinic; offered at the consultant's discretion in selected patients.
• Reading test — once a week, cover one eye and read normal newsprint at usual distance; ring same-day if reading drops in one eye.
• Inter-injection symptoms — new floaters, flashes of light, sudden blur, eye pain, redness or discharge in the days after an injection: ring 0800 852 7782.
• AREDS2 vitamins, Mediterranean diet, smoking cessation, BP and cholesterol control — protect the fellow eye and slow the dry-AMD background.

How to choose a London wet AMD clinic in 2026

1. CQC registration and Good rating — check the clinic's published CQC report.
2. Consultant medical retina fellowship — the injecting consultant should hold a UK medical retina fellowship and be a member of BEAVRS, the RCO Medical Retina SIG and EURETINA.
3. High annual injection volume — ask for the surgeon's annual intravitreal anti-VEGF volume; look for > 500 injections per year.
4. Same-day OCT, OCTA and FFA — on-site Spectralis or Cirrus OCT, OCTA and FFA capability without a separate appointment.
5. Sterile clean-room procedure suite — injections performed in a CQC-registered clean-room environment, not at the slit lamp.
6. Drug-of-choice flexibility — clinic stocks Eylea HD, Vabysmo, Eylea 2 mg, Lucentis, biosimilars and Beovu, with an off-label Avastin compounding pathway.
7. Treat-and-extend protocol in place — written T&E policy with same-day OCT and same-day injection.
8. Out-of-hours consultant access — 24/7 cover for any new central distortion, pain, redness or vision drop.
9. Insurance billing experience — the billing team knows the cap rules for Bupa, AXA, Aviva, Vitality and WPA.

Frequently asked questions

How much does a private anti-VEGF injection for wet AMD cost in London in 2026?

A single private intravitreal anti-VEGF injection for wet AMD typically costs £900–£1,800 per eye in London in 2026, drug-dependent. Eylea HD 8 mg aflibercept and Vabysmo (faricimab 6 mg) sit at the top of the range; Eylea 2 mg, Lucentis (ranibizumab 0.5 mg) and ranibizumab biosimilars (Byooviz, Ximluci) sit in the middle; off-label Avastin (bevacizumab 1.25 mg) is the cheapest. The all-inclusive fee covers the consultant medical retina specialist, the drug, the sterile injection pack, OCT and structured 4-week follow-up.

How many anti-VEGF injections will I need for wet AMD?

Almost all wet AMD patients start with three monthly loading injections at weeks 0, 4 and 8. Maintenance is then individualised on a treat-and-extend (T&E) protocol: the consultant extends the interval by 2-week steps when the macula is dry on OCT and shortens it by 2-week steps when fluid recurs. Most patients reach a maintenance interval of 8–16 weeks; Eylea HD 8 mg and Vabysmo can extend many patients to 12, 16 or 20 weeks within 12–24 months.

What is the difference between Eylea, Eylea HD, Vabysmo, Lucentis and Beovu?

All five drugs block VEGF and dry up abnormal new blood vessels under the retina. Eylea (aflibercept 2 mg) and Lucentis (ranibizumab 0.5 mg) are the original gold-standard agents. Eylea HD (aflibercept 8 mg) is a four-fold higher-dose formulation with longer dosing intervals (PULSAR 96-week trial). Vabysmo (faricimab 6 mg) blocks both VEGF-A and angiopoietin-2 (TENAYA / LUCERNE). Beovu (brolucizumab 6 mg) is a single-chain antibody fragment with longer durability but a higher rate of intra-ocular inflammation. The consultant recommends the right drug for your phenotype.

Will my wet AMD vision improve with anti-VEGF injections?

Pivotal trials (CATT, IVAN, VIEW, HARBOR, TENAYA / LUCERNE, PULSAR) and the UK NHS Liverpool real-world dataset show that around 30–40 per cent of patients gain three or more lines of vision (15 ETDRS letters) at 12 months, around 90 per cent stabilise (lose less than 15 letters) and around 5–10 per cent continue to lose vision despite optimal treatment. Earlier diagnosis and a complete loading-plus-T&E protocol are the strongest predictors of a good visual outcome.

Are anti-VEGF injections painful?

No. The eye is anaesthetised with topical proxymetacaine drops and a sub-conjunctival lidocaine pledget. The 30–32-gauge injection takes around two seconds and most patients feel pressure rather than pain. There is mild gritty discomfort for 12–24 hours from the iodine prep; floaters and small subconjunctival haemorrhages are common and self-limiting.

What are the risks of intravitreal anti-VEGF injections?

Endophthalmitis (sight-threatening intra-ocular infection) occurs in around 1 in 2,000 to 1 in 5,000 injections. Sterile intra-ocular inflammation is around 1 in 200 to 1 in 1,000 (higher with brolucizumab). Retinal detachment, cataract progression, transient IOP spike, sub-conjunctival haemorrhage and floaters are well-recognised. Systemic risk of stroke or MI remains a topic of debate; current UK consensus is that the risk is small and is outweighed by the visual benefit in wet AMD.

Is wet AMD treatment available on the NHS in 2026?

Yes. Wet AMD is funded on the NHS under NICE TA155 (ranibizumab), TA294 (aflibercept), TA672 (faricimab) and TA800 (aflibercept HD 8 mg, 2024). The current NHS challenge is capacity, not commissioning: most UK NHS macular clinics run a 1–4 week wait between diagnosis and the first injection. The private same-day pathway is selected when same-day diagnosis-to-injection matters, when a specific newer drug (Eylea HD or Vabysmo) is preferred or when work, geography or consultant continuity make the private route the safer choice.

Will my private medical insurance cover wet AMD injections?

Bupa, AXA Health, Aviva, Vitality and WPA cover diagnosis and full treatment of wet AMD with intravitreal anti-VEGF injections in 2026 with pre-authorisation. The clinic billing team typically obtains pre-authorisation in 24–48 hours. Some policies cap the number of injections per year or per condition; check your policy. Newer drugs (Eylea HD, Vabysmo) are usually reimbursed at the same rate as Eylea 2 mg or Lucentis once the consultant has documented the clinical rationale.

What if I miss an injection?

Missing or significantly delaying a maintenance injection is the most common reversible cause of vision loss in wet AMD. If you miss your scheduled date, ring the clinic the same day; the consultant team will rebook you within 7–14 days, scan the macula and reset the treat-and-extend interval. The 0800 852 7782 line is staffed 7 days a week.

Can the eye drops or oral drugs replace injections for wet AMD?

Not in 2026. Topical OPT-302 (sozinibercept), oral inhibitors and gene therapy (RGX-314 ABBV-RGX-314, 4D-150) are in late-phase trials and may extend treatment intervals further or reduce injection burden, but intravitreal anti-VEGF remains the standard of care. The consultant team will discuss any open UK trial that you are eligible for.

How quickly can I be seen privately for new wet AMD symptoms?

Same-day or next-day. New central distortion (a wavy line on the Amsler grid), a new central blind spot or sudden central visual blur in a patient over 50 with known dry AMD is treated as a medical retina emergency. Ring 0800 852 7782 as soon as symptoms start; the clinic will arrange same-day OCT, OCT angiography and consultant medical retina assessment, with the first loading injection given the same day where indicated.

What is the difference between dry and wet AMD?

Dry (non-neovascular) AMD is the slow drusen-and-atrophy form that affects around 90 per cent of AMD patients; treatment is AREDS2 vitamins, lifestyle modification and (in the US) complement-inhibitor injections for geographic atrophy. Wet (neovascular) AMD is the abrupt new-vessel-and-fluid form that affects around 10 per cent and causes the majority of severe AMD vision loss; it is treated with intravitreal anti-VEGF injections.

Sources and editorial methodology

This guide is compiled from UK 2026 self-pay tariffs published by major London CQC-registered medical retina centres, NICE TA155 (ranibizumab), TA294 (aflibercept), TA672 (faricimab) and TA800 (aflibercept HD 8 mg, 2024), Royal College of Ophthalmologists Medical Retina Commissioning Standards and Intravitreal Injection Standards, the British and Eire Association of Vitreoretinal Surgeons (BEAVRS) consensus, EURETINA wet AMD position statement, AAO Preferred Practice Pattern (Age-Related Macular Degeneration), and the CATT, IVAN, MARINA, ANCHOR, VIEW 1 and 2, HARBOR, TENAYA / LUCERNE, PULSAR, HAWK / HARRIER pivotal trials and the UK NHS Liverpool real-world dataset. Reviewed by a UK GMC-registered consultant ophthalmologist with medical retina subspecialty fellowship. Last updated May 2026. Prices are provider-published and inclusive of consultant, drug, sterile clean-room injection pack, OCT and structured follow-up unless stated otherwise.

Book your private wet AMD assessment in London

Same-day consultant medical retina review, OCT, OCT angiography and (where indicated) FFA. First loading anti-VEGF injection given the same day. Bupa, AXA, Aviva, Vitality and WPA pre-authorisation in 24–48 hours.